MSLN and pancreatic neoplasm: used 89Zr‐labeled TfR‐targeting mAb TSP‐A01 to image a mouse pancreatic cancer model, showing that 89Zr‐labeled TSP‐A01 clearly visualized MiaPaCa‐2 tumors with high TfR expression.[47] Similarly, immune‐PET imaging targets mesothelin (MSLN) overexpression, a prognostic marker in pancreatic cancer.